Skip to main content

14-11-2019 | Rheumatology | News | Article

ACR/ARP 2019 news in brief

Sustained benefits of ixekizumab over adalimumab in PsA

medwireNews: Follow-up results from the SPIRIT-H2H trial indicate that ixekizumab continues to improve joint and skin symptoms relative to adalimumab after 1 year of treatment among patients with psoriatic arthritis (PsA).

As reported previously by medwireNews, the primary results of SPIRIT-H2H demonstrated that a significantly greater proportion of patients given ixekizumab versus placebo achieved the primary endpoint of both an ACR50 and a PASI100 response at week 24, at 36% versus 28%.

Reporting the follow-up results at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA, Josef Smolen (Medical University of Vienna, Austria) said that the 283 ixekizumab-treated treated patients continued to have a significantly higher likelihood of meeting the composite endpoint than the 283 given adalimumab, with 39% versus 26% achieving this at 1 year. The between-group difference at 1 year remained statistically significant in patients who were not receiving methotrexate (40 vs 20%), but lost significance for those receiving concomitant methotrexate (39 vs 30%).

In line with the 24-week results, ACR20, 50, and 70 response rates remained comparable in the two groups at 1 year, as did improvements in HAQ-DI scores.

Smolen said that the 1-year safety findings for ixekizumab and adalimumab “were consistent with previously established safety profiles” for both drugs. A total of 74% and 69% of patients in the ixekizumab and adalimumab arms, respectively, experienced treatment-emergent adverse events (TEAEs), and a corresponding 4.2% and 7.4% discontinued treatment due to TEAEs.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology

Arthritis Rheumatol 2019; 71 (suppl 10)

Related content

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits